Flash note: Achieved proof-of-concept for BuTab
Today, Relmada announced that its pharmacokinetic (PK) study in 30 healthy volunteers for BuTab, its orally ingestible formulation of buprenorphine, was successful and achieved safe and effective blood levels of the drug. As a reminder, currently none of the marketed forms of buprenorphine (which have >$1bn annual sales in the US combined) can be swallowed as they are sublingual, buccal or patch formulations.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.